China Touyun Tech Group (1332) AI Stock Analysis

• Market Cap: HK$1.07B
• Dividend Yield: N/A
• Average Volume (3M): 711.77K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.18
• Revenue Growth: -30.86%
• EPS Growth: 87.59%
• Country: HK
• Employees: 485
• Sector: Consumer Cyclical
• Sector Strength: 84
• Industry: Packaging & Containers
• EPS (TTM): <0.01
• Shares Outstanding: 2,805,952,100
• 10 Day Avg. Volume: 262,687
• 30 Day Avg. Volume: 711,770
• PEG Ratio: 0.09
• Price to Book (P/B): -6.27
• Price to Sales (P/S): 3.26
• P/FCF Ratio: -9.75
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 47 Neutral
• Price Target: HK$0.30 ▲(0.00% Upside)

The overall stock score reflects significant financial challenges, including negative profitability and a strained balance sheet. While technical analysis shows some positive momentum, the valuation remains unattractive due to ongoing losses and the absence of a dividend yield.

Positive Factors

Industry Demand

Growing demand for digital transformation supports long-term revenue potential, as industries increasingly adopt cloud, AI, and big data solutions.

Partnerships and Collaborations

Strategic partnerships can enhance technological capabilities and market reach, fostering innovation and potentially leading to joint ventures.

Product Offering

Innovative product offerings in cloud computing, AI, and big data position the company to capitalize on technological advancements and industry needs.

Negative Factors

Declining Revenue

Declining revenues indicate potential market share loss or reduced demand, impacting long-term growth and financial stability.

Negative Profitability

Sustained negative profitability suggests operational inefficiencies and may limit reinvestment in growth initiatives, affecting future competitiveness.

Balance Sheet Stress

Negative equity and high leverage increase financial risk, limiting the company's ability to secure financing and invest in strategic opportunities.

China Touyun Tech Group Business Overview & Revenue Model

Company Description

Touyun Biotech Group Limited, an investment holding company, designs, develops, manufactures, and sells packaging products in Hong Kong, the People's Republic of China, Europe, North and South America, and internationally. It operates through four segments: QR Code Business, Packaging Products, Treasury Investment, and Chlamydomonas Reinhardtii Product Business. The QR Code Business segment provides QR codes on product packaging and solutions, and advertising display services. The Packaging Products segment manufactures and sells watch and jewelry boxes, eyewear cases, bags and pouches, and display units. The Treasury Investment segment invests and trades in securities, as well as offers money lending, placing and underwriting, securities brokerage, asset management, and margin financing services. The Chlamydomonas Reinhardtii Product Business segment produces and sells chlamydomonas reinhardtii, micro-algae, and related products. It also provides business intelligence IT solutions, online advertising display, and corporate management services. The company was formerly known as China Touyun Tech Group Limited and changed its name to Touyun Biotech Group Limited in May 2021. Touyun Biotech Group Limited was founded in 1989 and is headquartered in Wan Chai, Hong Kong.

How the Company Makes Money

China Touyun Tech Group generates revenue through multiple streams, including subscription fees for its cloud services, licensing fees for its software products, and consulting services related to big data and AI implementation. Additionally, the company collaborates with key industry players, leveraging partnerships to expand its market reach and enhance its technology offerings. These collaborations often lead to joint ventures or co-development projects, further contributing to its earnings. The increasing demand for digital transformation across industries serves as a significant driver of revenue growth for the company.

China Touyun Tech Group Financial Statement Overview

Summary

The company faces significant financial challenges with declining revenues, negative profitability, and a strained balance sheet. Negative equity and high leverage pose substantial risks, while cash flow constraints limit strategic options.

Income Statement

The income statement reflects a challenging financial position with declining revenues and negative profit margins. The gross profit margin is positive but has deteriorated over time, indicating rising costs or pricing pressures. EBIT and EBITDA margins are negative, suggesting operational inefficiencies or high fixed costs. Net income remains negative, highlighting ongoing profitability challenges.

Balance Sheet

The balance sheet shows significant financial stress with negative stockholders' equity, indicating insolvency. The debt-to-equity ratio is not meaningful due to negative equity, but total debt is substantial compared to assets. Despite a decrease in total assets, liabilities have increased, further weakening the financial position. The equity ratio is negative, emphasizing the company's reliance on debt financing.

Cash Flow

Cash flow analysis reveals weak operational cash generation with zero operating cash flow in the latest period. Free cash flow has been negative, indicating cash burn and insufficient cash flow to cover capital expenditures. The absence of recent positive cash flow metrics limits financial flexibility and investment capacity.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	117.22M	159.97M	198.64M	315.82M	283.50M	206.79M
Gross Profit	49.21M	72.07M	56.60M	120.12M	107.05M	84.61M
EBITDA	-34.16M	-27.92M	-228.57M	-144.39M	-83.13M	-87.22M
Net Income	-28.89M	-88.11M	-268.94M	-198.06M	-72.95M	-168.78M
Balance Sheet
Total Assets	613.22M	550.32M	607.34M	887.70M	1.02B	971.94M
Cash, Cash Equivalents and Short-Term Investments	11.53M	69.64M	36.04M	144.25M	93.95M	254.40M
Total Debt	400.72M	384.59M	384.91M	395.01M	317.37M	222.62M
Total Liabilities	619.38M	590.96M	586.27M	604.19M	537.68M	415.57M
Stockholders Equity	-63.84M	-83.20M	-848.00K	263.96M	469.92M	488.04M
Cash Flow
Free Cash Flow	-1.94M	-53.54M	-13.49M	-39.30M	-304.60M	-140.86M
Operating Cash Flow	431.00K	-49.87M	3.65M	-26.37M	-53.81M	-15.35M
Investing Cash Flow	23.99M	-4.66M	-70.95M	-17.25M	-147.74M	-47.87M
Financing Cash Flow	23.37M	35.74M	-27.68M	102.63M	123.17M	160.47M

China Touyun Tech Group Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 0.30
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1332, the sentiment is Neutral. The current price of 0.3 is below the 20-day moving average (MA) of 0.32, above the 50-day MA of 0.22, and above the 200-day MA of 0.15, indicating a neutral trend. The MACD of 0.02 indicates Positive momentum. The RSI at 51.73 is Neutral, neither overbought nor oversold. The STOCH value of 17.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1332.

China Touyun Tech Group Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$18.38B	12.79	-2.54%	3.03%	1.52%	-15.83%
6898	58 Neutral	HK$670.27M	42.01	13.20%	0.58%	-2.08%	-23.18%
1626	49 Neutral	HK$1.65B	-149.46	-7.35%	―	-82.87%	-110.99%
1332	47 Neutral	HK$1.07B	-36.89	―	―	-30.86%	87.59%
1820	46 Neutral	HK$748.57M	―	-5.51%	3.20%	3.51%	-950.83%
8291	45 Neutral	HK$13.60M	3.08	―	―	-44.08%	―
0252	45 Neutral	HK$360.67M	―	-2.11%	1.87%	19.02%	-236.72%

China Touyun Tech Group Corporate Events

Touyun Biotech Announces CEO Remuneration Changes

Touyun Biotech Group Limited has released supplemental information related to the remuneration of its CEO, Ms. Amy Ha, for the years 2022 and 2023. The announcement highlights a significant decrease in her remuneration from HK$3,102,000 in 2022 to HK$16,000 in 2023, which may indicate a strategic financial adjustment within the company.

Touyun Biotech Announces Strategic Cooperation Amid Unusual Market Activity

Touyun Biotech Group Limited announced an unusual increase in its share price and trading volume, with no known reasons for these movements. The company confirmed that its operations remain normal and disclosed a strategic cooperation agreement with a sales consortium to purchase Chlamydomonas reinhardtii products worth at least RMB1 billion from 2026 to 2028, indicating potential growth opportunities.

Touyun Biotech Group Implements Strategic Measures to Address Financial Concerns

Touyun Biotech Group Limited has announced several strategic measures to address a disclaimer of opinion on its financial statements. These measures include launching new health products, securing financial support from directors and shareholders, obtaining new loans, and negotiating loan extensions. Additionally, the company is exploring options to increase working capital through asset disposals and enhancing product distribution through partnerships with supermarket chains and collaborations with Key Opinion Leaders. These initiatives aim to resolve uncertainties related to the company’s going concern status and improve its financial stability.

Touyun Biotech Announces Change in Share Registrar

Touyun Biotech Group Limited has announced a change in its Hong Kong Branch Share Registrar and Transfer Office, effective from 30 September 2025. The new registrar will be Tricor Investor Services Limited, and stakeholders are advised to lodge applications for share transfers with the new office from the specified date. This change is part of the company’s operational updates, potentially impacting how shareholders manage their share transactions.